Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
212Pb-TCMC-trastuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Orano Med
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (trastuzumab), Intraperitoneal (212Pb-TCMC-trastuzumab)
01
Overview
This is a **combination therapy** consisting of **212Pb-TCMC-trastuzumab**, a radiolabeled monoclonal antibody with the chelator TCMC binding the alpha-emitting isotope lead-212 (^212Pb^) to trastuzumab, plus **trastuzumab**, a humanized monoclonal antibody targeting HER2/neu. 212Pb-TCMC-trastuzumab delivers targeted alpha-particle radiotherapy directly to HER2-expressing cancer cells, inducing DNA damage, cell cycle arrest, and apoptosis via ionizing radiation. The added trastuzumab component provides immune-mediated antitumor mechanisms and may optimize targeting and distribution. This combination is experimental and primarily investigated for peritoneal metastases of HER2-positive cancers, notably ovarian and gastrointestinal malignancies, especially in cases refractory to standard treatments[1][2][4][3].
- Other names
- 212Pb-TCMC-trastuzumab + trastuzumab
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 212Pb-TCMC-trastuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 212Pb-TCMC-trastuzumab + trastuzumab.